Crispr Therapeutics is trading at $56.42, up 4.32%, with no clear company-specific catalyst identified for the September 29 move.
- A September 29 article discussed two expected clinical-trial updates before year-end, but reported no new results and did not link the updates to the day’s gain.
- Broader indices were slightly lower in the supplied market context, which does not establish a market-wide reason for the rise. Intraday volume details were unavailable.